Top ten stories in the pharmaceutical industry this week

pharmafile | August 5, 2016 | News story | Medical Communications, Research and Development Actavis, Bioelectronics, CDF, Celgne, EMA, GSK, GlaxoSmithKline, Innovate UK, Medivation, NICE, Novartis, Roche, Sanofi, Teva, appointments, apremilast, biog, breast cancer, brexit, google, pharmaceutical industry, rheumatoid arthritis, sarilumab, top ten 

It’s Friday, and we’ve seen some big developments in the industry’s headlines throughout the week, from news of Glaxo-Smith-Kilne’s new bioelectronics partnership with Google to the completion of Teva’s long-delayed acquisition of Actavis Generics. But far and away the most read story this week is Vincenzo Salvatore’s feature outlining his predictions on the impact Brexit will have on the pharma industry.

1. The impact of Brexit on the pharmaceutical industry: some preliminary considerations

The outcome of the popular vote cast on 23 June 2016 will be remembered as the start of a new era in the history of UK-EU relations

2. GSK and Alphabet to create bioelectronics medicines in £540 million partnership

The companies have come together to form Galvani Bioelectronics, which will be headquartered in the UK

3. Teva completes $40 billion acquisition of Actavis Generics

The pharmaceutical firm reports it is “stronger than ever” after assimilating Allergan’s subsidiary

4. American pharmacy adds 35 products to list of excluded drugs

Medivation’s prostate cancer drug Xtandi and Sanofi’s insulin Lantus are among those added to the list

5. NICE recommends Celgene’s apremilast for NHS use

The decision follows the organisation’s rejection of the drug last year

6. Innovate UK appoints first director of Health and Life Sciences

Ian Campbell has been named by the company UK as its first director in the newly created position

7. Breakthrough therapy designation for Novartis in advanced breast cancer treatment

LEE011 (ribociclib) is under investigation in HR+/HER2- advanced breast cancer

8. EMA accepts MMA for rheumatoid arthritis treatment Sarilumab

Sanofi and Regeneron announce acceptance of marketing authorisation application for new drug

9. Roche urges reform of Cancer Drugs Fund as NICE takes control

UK general manager Richard Erwin has called for government action on a drug appraisal system that “is broken at both ends”

10. Takeover rumours send Biogen’s stock soaring

Allergan and MSD are said to be considering a big for the Massachusetts biotech, whose current market cap is $75.3 billion

Matt Fellows

Related Content

FDA approves Novartis’ Fabhalta for PNH treatment

Novartis has announced that the US Food and Drug Administration has approved Fabhalta (iptacopan) as …

Genentech shares positive results from phase 3 trial for breast cancer treatment

Genentech, a member of the Roche Group, has announced positive results from the phase 3 …

Roche to acquire Carmot Therapeutics for $2.7bn

Roche has announced that it has entered into a definitive merger agreement with Carmot Therapeutics, …

Latest content